Phase I/II enzyme gene polymorphisms and esophageal cancer risk: A meta-analysis of the literature

Table 3 Summary of the meta-analysis of GSTM1, GSTTI and esophageal cancer risk.

Study	Country	Cases	Controls	Case	Case	Control	Control	OR (95%CI)
GSTM1:				Non-null	Null	Non-null	Null
Hori H	Japan	94	428	53	41	232	196	0.92 (0.57-1.47)
Nimura Y	China	89	137	42	47	74	63	1.31 (0.74-2.32)
Morita S	Japan	53	132	30	23	77	55	1.1 (0.6-2.0)
Lin DX	China	45	45	25	20	24	21	1.0 (0.4-2.3)3
van Lieshout EM	Netherlands	34	247	17	17	119	128	0.93 (0.42-2.04)
Shao G	China	107	111	68	39	56	55	1.76 (1.03-2.74)
Tan W	China	150	150	104	46	74	76	0.43 (0.33-0.56)34
Yokoyama A	Japan	234	634	131	103	313	321	0.77 (0.56-1.05)
Gao CM	China	141	223	35	106	90	133	2.17 (1.35-3.50)3
Wang LD	China	62	38	35	27	19	19	0.77 (0.32-1.88)
Casson AG	Canada	45	45	19	26	20	25	1.1 (0.5-2.7)3
Wang AH	China	127	101	53	74	57	44	1.81 (1.03-3.18)
Meta-analysis	results	1181	2291	612	569	1155	1136	1.07 (0.76-1.51)
GSTT1:
Lin DX	China	45	45	26	19	22	23	0.7 (0.3-1.5)3
van Lieshout EM	Netherlands	34	247	28	6	198	49	0.87 (0.28-2.29)
Tan W	China	150	150	90	60	91	59	1.11 (0.83-1.43)34
Gao CM	China	141	223	67	74	104	119	0.90 (0.59-1.39)3
Wang LD	China	62	38	28	34	18	20	1.09 (0.45-2.65)
Casson AG	Canada	45	45	37	8	33	12	0.6 (0.2-1.7)3
Meta-analysis results		477	748	276	201	466	282	0.99 (0.80-1.22)

¹Non-null genotype as the reference group. ²All the ORs were crude values calculated from the genotype distribution except in places denoted by^{3, 4}.

³indicates cases where the adjusted OR in the report was used and

⁴where the OR value was inverted.